Trials / Completed
CompletedNCT02282930
Pilot Study of ACTH in the Treatment of Immunoglobulin A (IgA) Nephropathy at High Risk of Progression
An Open-Label Pilot Study of ACTH in the Treatment of IgA Nephropathy at High Risk of Progression
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 20 (actual)
- Sponsor
- Mayo Clinic · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study is designed to answer whether patients with progressive IgA nephropathy, who receive Acthar (ACTH) gel injection at a dose of 80 units subcutaneously twice weekly for 6 months is effective in inducing improvement in proteinuria and renal function.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ACTH (Acthar) Gel | Injected dose of 80 units subcutaneously twice weekly for 6 months. |
Timeline
- Start date
- 2015-03-01
- Primary completion
- 2018-06-30
- Completion
- 2018-06-30
- First posted
- 2014-11-05
- Last updated
- 2019-06-26
- Results posted
- 2019-06-26
Locations
4 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT02282930. Inclusion in this directory is not an endorsement.